NOW
APPROVED!
Once monthly maintenance dosing after 18 months1
Start LEQEMBI®. Change the course of AD1,2
In an 18-month study, LEQEMBI was proven to slow the progression of MCI due to AD and mild AD dementia. Learn more:
MCI=mild cognitive impairment.
Once-monthly maintenance dosing now available.
The initial dose is twice monthly (once every two weeks). After 18 months, twice-monthly dosing may be continued, or a transition to the maintenance dosing of once monthly (once every four weeks) may be considered.1
To learn about Eisai Patient Support for patients prescribed LEQEMBI, call 1-833-4-LEQEMBI (1-833-453-7362) or click here.
